FiercePharma12h
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Pharmabiz1h
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
PharmiWeb23h
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
A Letter from the Editor: What to Know About Metastatic Breast Cancer in Young Women
With cancer rising in women under 40, there's concern about the causes — and the effects. PEOPLE's editor-in-chief Charlotte ...
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...
Targeted Oncology10h
HR+/MP-H2 Breast Cancers Resemble Triple-Negative, Guiding New Therapies
Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as ...
BioPharma Dive15h
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...
Fred Hutch14h
New methods reveal cancer mechanism in ancient genes
Researchers at Fred Hutch Cancer Center have discovered an overlooked mechanism driving aggressive breast and brain tumors ...